patients who have type 2 diabetes or obesity have a higher risk of developing cáncer, así as a worst-pron’plastic when the disease is already manifest and converge both patologías, s&number;n ha&bath;winged dr. Enrique Palacio, head of the department of Endocrinología del Hospital Nuestra Se&bath;ora de la Candelaria in the framework of the symposium ‘The security of análogos of insulin’. In Espa&bath;it is estimated that type 2 diabetes affects 4.6 million people; approximately one-third of them not están diagnosed, and that práalmost half of the patients with diabetes are obese.
For this reason, this expert&bath;wing, these patients must control the weight to get a better control metab’officials, "which in turn is much más fácil if you have a healthy weight if overweight". It also has explained that "obesity and overweight increase the likelihood of developing hipertensi’n, cholesterol, or patologícardiovascular". The data available up to now indicate that 60 per cent of the patients did not reach a control ’ptimo of the disease, that is to say, of the 246 million people with type 2 diabetes in the world, around 150 million have a blood glucose level higher than the target. In this regard, this expert has reminded that "the control of the glucose levels in the patient with diabetes is essential, given that not meeting a control metab’lico may involve lesions in m&number;multiple tissues, including the retina, the ri&bathrooms;ones and the cardiovascular system. People with diabetes, for example, have between 15 and 40 times más risk of suffering a amputaci’n of the lower limb, and increase the chance of cardiovascular disease". During the meeting, held in Santa Cruz de Tenerife with the collaboration’n of Novo Nordisk, dr. Arturo Rolla, professor of Medicine Clínica at the University of Harvard in Boston, Massachusetts, says that "the fact that obesity and diabetes increase the risk of cáncer, couldíto be due to the activity of tr’fica of insulin, in general". For this reason, remember the importance of controlling the glycemia and the glycosylated hemoglobin, as&bath;wing, además "reduces complications cr’nicas of the diabetes". For a control terapétherapeutic ’ptimo have remembered that the análogos of insulin have improved the treatment of diabetes in the &number;last&years, to such an extent that they have become the option’n terapéutica más effective. S&number;n Rolla, "análogos de acci’n ráask to allow a better control of postprandial glucose with the convenience of the patients may be injected before meals, while for their part, the análogos, full-length’n improve the quality of life of patients, given its less variability as they last 24 hours and does not have a peak of activity very defendant".